Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms
EVFM(EVFM) -- 130% increase in traffic to PHEXXI.com, the website for Evofem's hormone-free prescription contraceptive PHEXXI® (lactic acid citric acid and potassium bitartrate) -- -- PHEXXI® is #1 most followed contraceptive brand on social media by healthcare providers -- SAN DIEGO, Sept. 11, 2025...
FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis
EVFM-- Evofem now holds eleven Orange Book - listed patents covering SOLOSEC into late 2041 -- SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCID: EVFM) today announced that a newly-issued U.S. patent which covers SOLOSEC® (secnidazole) 2 g oral granules and one of its...
Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update
EVFM-- Increased Net Sales and Improved Loss from Operations in Q2 2025 vs. Prior Year Quarter -- -- Evofem Advances Plans for Special Meeting of Stockholders to Approve the A&R Merger Agreement and Become a Wholly-owned Subsidiary of Aditxt -- SAN DIEGO, Aug. 14, 2025 /PRNewswire/ -- Women's...
Evofem Biosciences Q1 Sales $845.00K Down From $3.60M YoY
EVFMEvofem Partners With Windtree Therapeutics to Slash PHEXXI Manufacturing Costs By 55%-60% Through New License And Supply Agreement; There Will Be No Cost To Evofem For The Tech Transfer To The New Manufacturer Engaged By Windtree.
EVFMWindtree Enters License And Supply Agreement To Become A Sourcing Partner For Evofem Biosciences For Evofem's PHEXXI
EVFMEvofem Biosciences Q1 Sales $4.30M Beat $4.15M Estimate
EVFM